Insulet Faces Securities Fraud Class Action Lawsuit
Insulet Corporation is facing a class action lawsuit alleging securities fraud. The suit claims the company misrepresented safety information regarding its Omnipod products, leading to a significant stock price drop.
Boston, MA – Insulet Corporation is the subject of a class action lawsuit alleging securities fraud, filed on behalf of investors who purchased the company's stock. The complaint, lodged in the U.S. District Court for the District of Massachusetts, contends that Insulet misrepresented the safety of its Omnipod insulin delivery systems.
The lawsuit points to a significant stock price decline of over 6% in March 2026, following Insulet's disclosure of manufacturing issues that caused internal tubing tears and potential insulin under-delivery. A subsequent voluntary medical device correction announced in May 2026 led to a further drop in the company's stock value.
Plaintiffs allege that Insulet and its executives misrepresented the safety of its products and its manufacturing capabilities, failing to disclose defects that posed risks to patients. The claims are brought under federal securities laws, specifically Sections 10(b) and 20(a) of the Securities Exchange Act.
Investors who purchased Insulet stock and suffered losses are encouraged to seek further information. The deadline for investors to petition the court to be appointed lead plaintiff is August 31, 2026. The case is captioned Hu v. Insulet Corporation et al., No. 26-cv-13062.